

European Respiratory Society Annual Congress 2013

Abstract Number: 2848

Publication Number: P3421

Abstract Group: 4.1. Clinical respiratory physiology, exercise and functional imaging

Keyword 1: Physiology **Keyword 2:** Hypoxia **Keyword 3:** Pulmonary hypertension

Title: Cerebral oxygenation in highlanders with high altitude pulmonary hypertension

Mr. Michael 11611 Furian michael.furian@usz.ch^{1,2}, Dr. Tsogyal D. 11612 Latshang latshang.tsogyal@usz.ch MD¹, Ms. Sayaka 11613 Aeschbacher sayaka.aeschbacher@gmail.com¹, Dr. Silvia 11614 Ulrich silvia.ulrich@usz.ch MD¹, Dr. Aizat K. 11615 Myrzaakmatova mak7171@mail.ru MD³, Prof. Dr Talant 11621 Sooronbaev sooronbaev@yahoo.com MD³, Prof. Dr Almaz 11629 Aldashev aldashev@gmail.com MD⁴ and Prof. Dr Konrad E. 11631 Bloch konrad.bloch@usz.ch MD². ¹ Pulmonary Division, University Hospital of Zurich, Zurich, Switzerland ; ² Institute of Human Movement Sciences and Sport, Federal Institute of Technology, Zurich, Switzerland ; ³ Pulmonary Division, National Center of Cardiology and Internal Medicine, Bishkek, Kyrgyzstan and ⁴ Molecular Biology Division, Research Institute for Molecular Biology and Medicine, Bishkek, Kyrgyzstan .

Body: Objective High altitude pulmonary hypertension (HAPH) is associated with sleep apnea. Since sleep apnea may impair cerebral tissue oxygenation (CTO) and cerebrovascular autoregulation we evaluated whether CTO and cerebrovascular response to changes in FiO₂ are reduced in highlanders with HAPH. Methods 17 highlanders with HAPH (mean±SD pulmonary artery pressure, mPAP, 35±3 mmHg) and 17 age-matched controls (mPAP 24±4 mmHg, P<0.01 vs. HAPH) were studied in Aksay, Kyrgyzstan, at 3250m. CTO by near-infrared spectroscopy, finger pulse oximetry (SpO₂), end-tidal PCO₂, and ECG were recorded while subjects breathed room air and 100% oxygen for 20 min each, in random order. Results In highlanders with HAPH on FiO₂ 0.21, SpO₂ was 89±2%, CTO 68±3%. In controls SpO₂ was 91±3% (P=0.01 vs. HAPH), CTO 67±4% (P=0.34). In highlanders with HAPH, breathing FiO₂ 1.0 increased SpO₂ by 9±3% (P<0.01), CTO by 5±2% (P<0.01) and reduced cerebral hemoglobin concentration (CHb), a surrogate of changes in cerebral blood volume by -1.4±1.6 relative units (P<0.01). In controls, breathing FiO₂ 1.0 increased SpO₂ by 7±2% (P<0.01 vs. FiO₂ 0.21; P=0.01 vs. HAPH) and CTO by 3±1% (P<0.01 vs. FiO₂ 0.21; P=0.11 vs. HAPH), and decreased CHb by -1.4±2.1 ru (P=0.03 vs. FiO₂ 0.21; P=0.73 vs. HAPH). Younger age and higher CTO on FiO₂ 0.21 were significantly correlated with hyperoxia-induced changes in CHb but changes in blood pressure and end-tidal PCO₂ were not. Conclusions In highlanders with HAPH arterial oxygen saturation is reduced but cerebral oxygenation and the cerebrovascular response to alterations in FiO₂ are not impaired. Thus, compensatory mechanisms may prevent cerebral hypoxia in HAPH patients. Grants: OPO Foundation, Zurich Lung League.